Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

PURPOSE: The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Attar, Eyal C., Johnson, Jeffrey L., Amrein, Philip C., Lozanski, Gerard, Wadleigh, Martha, DeAngelo, Daniel J., Kolitz, Jonathan E., Powell, Bayard L., Voorhees, Peter, Wang, Eunice S., Blum, William, Stone, Richard M., Marcucci, Guido, Bloomfield, Clara D., Moser, Barry, Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577952/
https://ncbi.nlm.nih.gov/pubmed/23129738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.2177
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados